Alzheimer's Medicines Approved in the EU (EMA)

• 24medicines authorised in the EU (authorised now)

Each number has its full source under its own list below.

• 24Sep2025

  Kisunla

  Active substance: donanemab

  EMEA/H/C/006024
• 15Apr2025

  Leqembi

  Active substance: Lecanemab

  EMEA/H/C/005966
• 22Aug2024

  Tauvid

  Active substance: Flortaucipir (18F)

  EMEA/H/C/006064
• 17Jun2021

  Celsunax

  Active substance: ioflupane (123i)

  EMEA/H/C/005135
• 25Jun2019

  Striascan

  Active substance: ioflupane (123l)

  EMEA/H/C/004745
• 22Aug2014

  Vizamyl

  Active substance: flutemetamol (18F)

  EMEA/H/C/002557
• 20Feb2014

  Neuraceq

  Active substance: florbetaben (18F)

  EMEA/H/C/002553
• 3Dec2013

  Memantine Accord

  Active substance: memantine hydrochloride

  EMEA/H/C/002766
• 12Jun2013

  Memantine ratiopharm

  Active substance: memantine hydrochloride

  EMEA/H/C/002671
• 28Apr2013

  Marixino (previously Maruxa)

  Active substance: memantine hydrochloride

  EMEA/H/C/002658
• 22Apr2013

  Nemdatine

  Active substance: memantine

  EMEA/H/C/002680
• 21Apr2013

  Memantine Mylan

  Active substance: memantine hydrochloride

  EMEA/H/C/002660
• 14Jan2013

  Amyvid

  Active substance: florbetapir (18F)

  EMEA/H/C/002422
• 22Nov2012

  Memantine Merz

  Active substance: memantine hydrochloride

  EMEA/H/C/002711
• 16Jun2011

  Rivastigmine Actavis

  Active substance: rivastigmine hydrogen tartrate

  EMEA/H/C/002036

Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.

• Clinical trials: Alzheimer's disease
• Alzheimer's disease death rate

• Brain and nerves